Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
E610067-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,334.90 | |
E610067-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $199.90 | |
E610067-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,001.90 | |
E610067-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $559.90 | |
E610067-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $779.90 |
Synonyms | Edicotinib|1142363-52-7|JNJ-40346527|Edicotinib [USAN]|JNJ40346527|3NU609VYNF|EdicotinibJNJ-40346527|Edicotinib (USAN)|4-Cyano-1H-imidazole-2-carboxylic acid N-(2-(4,4-dimethylcyclohex-1-enyl)-6-(2,2,6,6-tetramethyltetrahydropyran-4-yl)pyridin-3-yl)amide| |
---|---|
Specifications & Purity | 98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Macrophage colony stimulating factor receptor inhibitor |
Product Description |
Edicotinib (JNJ-40346527) is a potent, selective, brain penetrant and orally active colony-stimulating factor-1 receptor (CSF-1R) inhibitor with an IC50 of 3.2 nM. Edicotinib exhibits less inhibitory effects on KIT and FLT3 with IC50 values of 20 nM and 190 nM, respectively. Edicotinib limits microglial expansion and attenuates microglial proliferation and neurodegeneration in mice. Edicotinib has the potential for Alzheimer’s disease and rheumatoid arthritis research.
|
ALogP | 4.3 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 5-cyano-N-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1H-imidazole-2-carboxamide |
---|---|
INCHI | InChI=1S/C27H35N5O2/c1-25(2)11-9-17(10-12-25)22-21(32-24(33)23-29-16-19(15-28)30-23)8-7-20(31-22)18-13-26(3,4)34-27(5,6)14-18/h7-9,16,18H,10-14H2,1-6H3,(H,29,30)(H,32,33) |
InChi Key | BNVPFDRNGHMRJS-UHFFFAOYSA-N |
Canonical SMILES | CC1(CCC(=CC1)C2=C(C=CC(=N2)C3CC(OC(C3)(C)C)(C)C)NC(=O)C4=NC=C(N4)C#N)C |
Isomeric SMILES | CC1(CCC(=CC1)C2=C(C=CC(=N2)C3CC(OC(C3)(C)C)(C)C)NC(=O)C4=NC=C(N4)C#N)C |
Alternate CAS | 1142363-52-7 |
PubChem CID | 25230468 |
MeSH Entry Terms | 4-cyano-N-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyl-tetrahydro-2H-pyran-4-yl)pyridin-3-yl)-1H-imidazole-2-carboxamide;JNJ-40346527 |
Molecular Weight | 461.60 |
BindingDB Ligand | 98634 |
---|---|
PubChem CID | 25230468 |
CAS Registry No. | 1142363-52-7 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
G2411176 | Certificate of Analysis | Mar 27, 2024 | E610067 |
G2411177 | Certificate of Analysis | Mar 27, 2024 | E610067 |
G2411178 | Certificate of Analysis | Mar 27, 2024 | E610067 |
G2411179 | Certificate of Analysis | Mar 27, 2024 | E610067 |
G2411185 | Certificate of Analysis | Mar 27, 2024 | E610067 |
G2411186 | Certificate of Analysis | Mar 27, 2024 | E610067 |
G2411190 | Certificate of Analysis | Mar 27, 2024 | E610067 |
G2411191 | Certificate of Analysis | Mar 27, 2024 | E610067 |
G2411192 | Certificate of Analysis | Mar 27, 2024 | E610067 |
G2411193 | Certificate of Analysis | Mar 27, 2024 | E610067 |
Starting at $230.90
Starting at $85.90
Starting at $165.90
Starting at $150.90
Starting at $180.90
Starting at $350.90
Starting at $450.90
Starting at $385.90
Starting at $253.90
Starting at $403.90
1. Genovese MC, Hsia E, Belkowski SM, Chien C, Masterson T, Thurmond RL, Manthey CL, Yan XD, Ge T, Franks C et al.. (2015) Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.. J Rheumatol, 42 (10): (1752-60). [PMID:26233509] |